
CRRC, the Chinese state owned company that is the world’s largest train maker, is set to gain a key foothold in Europe by acquiring its first locomotive factory on the continent through a deal with German manufacturer Vossloh.
The deal comes as CRRC is under pressure in the US where it has opened two factories and won contracts to supply train cars for transit systems in several major American cities. Both houses of Congress have passed measures that would bar the use of federal funds to buy Chinese rail cars and buses out of concern they could be utilized for Chinese espionage or sabotage. It is not yet clear if the final version of the bill to which the ban has been attached will ultimately include it.
Vossloh announced Monday, September 2, that it would sell a locomotive factory it opened last year to CRRC Zhuzhou Locomotive, a subsidiary of Hong Kong-listed CRRC. The German company, which is narrowing its focus to railway infrastructure equipment, stated it expected to initially receive a figure in the “low single-digit millions of euros,” and another €10 million (US$11 million) in follow-on transactions, under its agreement with CRRC Zhuzhou.
Full Content: RailiJournal, Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas